Although attempts to directly target fibroblasts, such as using FAP-directed agents, have not met with success thus far, exploring alternative tactics that counteract the pro-tumoral activities of fibroblasts in mTLS-positive NSCLC is warranted.44 The gene discussed is FAP; the disease is non-small cell lung carcinoma.